The global value of generic, biosimilar and value added medicines
For the first time, Medicines for Europe and IGBA joined forces to create an opportunity to learn about global developments in generic, biosimilar and value added medicines. Our joint 22nd Medicines for Europe and 19th IGBA Annual Conference delivered a unique platform for you to meet and network with industry, regulators and key stakeholders from all over the world.
At the 2016 Conference in Dubrovnik, attendees had the opportunity to:
* Discover new strategic business opportunities
* Gain insight into the latest market developments
* Discuss sustainable healthcare systems with payers, regulators and policy makers
Last year’s EGA Annual Conference in Berlin was attended by 250 delegates representing more than 190 companies and organisations from over 30 different countries worldwide.
Christoph Stoller Senior Vice President Generics and Commercial Operations Europe, Teva - Vice-President, Medicines for Europe
Martin Albert Head of Portfolio & Program Management, Sanofi Generics
About the IGPA now IGBA
The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines. Its membership includes the Medicines for Europe (formerly EGA – Europe), the CGPA (Canada), the GPhA (USA), the JAPM (Jordan), the NAPM (South Africa), the TGPA (Taiwan) and the JGA (Japan) while the associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI) are Associate Members. The IGBA is at the forefront of stimulating competitiveness and innovation in the pharmaceutical sector by providing high quality pro-competitive medicines to millions of patients around the world. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities (including the European Commission for Europe) as well as with international institutions such as WTO, WIPO and WHO. More information: www.igbamedicines.org